Core Viewpoint - The company has received a medical device registration certificate for its myoglobin assay kit, which is intended for the quantitative measurement of myoglobin levels in human serum or plasma, aiding in the diagnosis of myocardial infarction [1] Group 1: Product Development - The myoglobin assay kit utilizes a latex immunoturbidimetric method [1] - The approval from the Guangdong Provincial Drug Administration enhances the company's portfolio in the "cardiovascular and myocardial markers" category of biochemical testing products [1] Group 2: Impact on Business - The introduction of this new product is expected to have a positive impact on the company's development [1] - However, it will not significantly affect the company's recent production operations and performance [1]

证券代码：300832 证券简称：新产业 公告编号：2026-004 深圳市新产业生物医学工程股份有限公司 关于公司产品获得 IVDR CE 认证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 新的欧盟体外诊断医疗器械法规（IVDR, EU 2017/746）替代原欧盟体外诊 断医疗器械指令（IVDD, 98/79/EC）对欧盟市场的体外诊断医疗器械进行管理。 截至目前，公司累计213项化学发光试剂产品、67项生化试剂产品获得IVDR CE 认证。 根据欧盟体外诊断医疗器械法规的规定，本次获得IVDR CE认证的产品已经 具备进入欧盟市场的必要条件，后续将进一步增强公司产品的综合竞争力，对公 司未来的经营将产生积极影响。上述产品实际销售情况取决于未来市场推广效果， 公司目前尚无法预测其对公司未来业绩的影响，敬请广大投资者注意投资风险。 特此公告。 深圳市新产业生物医学工程股份有限公司 董事会 2026 年 1 月 20 日 1 近日，深圳市新产业生物医学工程股份有限公司（以下简称"公司"）梅毒 螺旋体抗体检测试剂盒（磁微粒化学发光法）获得了由欧盟公告机 ...

关于获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，深圳市新产业生物医学工程股份有限公司（以下简称"公司"）收到 了广东省药品监督管理局颁发的 1 项《医疗器械注册证》。具体情况如下： | | | 粤械注准 | | 年 | 月 | 日至 | 本试剂盒用于体外定量测 定人血清或血浆中的肌红 | | --- | --- | --- | --- | --- | --- | --- | --- | | 盒（胶乳免疫比浊 | Ⅱ类 | | 2026 | 01 | | 16 | | | 法） | | 20262400080 | 2031 | 年 01 | 月 | 日 15 | 蛋白含量。临床上用于心 | | 产品名称 肌红蛋白测定试剂 | 注册 分类 | 注册证编号 | | | 注册证有效期 | | 适用范围 肌梗死的辅助诊断。 | 证券代码：300832 证券简称：新产业 公告编号：2026-003 深圳市新产业生物医学工程股份有限公司 二、对公司的影响及风险提示 深圳市新产业生物医学工程股份有限公司 董事会 2026 年 1 月 20 ...

Core Insights - Strategic emerging industries have become the core battlefield for state-owned enterprises (SOEs) to explore a "second growth curve" under the national strategy of cultivating new productive forces [1] Group 1: Industry Overview - A report by Zhongzhi Consulting indicates that among 402 SOE-controlled A-share listed companies, 257 have over 30% of their revenue from strategic emerging industries, which are included in the study [6] - By the end of 2024, strategic emerging industry enterprises are expected to contribute 26% of operating income and 31.27% of total profit with approximately 25% of total assets, showing a net asset return rate superior to traditional industries [7] Group 2: Structural Layout - Nearly 80% of enterprises focus on advantageous fields such as new-generation information technology, new materials, and new energy, but there is a relative weakness in key areas like industrial mother machines and biomanufacturing, necessitating increased investment to enhance industry influence [8] - 43.85% of manufacturing enterprises in strategic emerging industries are actively upgrading to high-value-added segments like new materials and high-end equipment, while the share of strategic emerging business in transportation and financial service companies is less than 1% [9] Group 3: R&D Investment - Overall R&D investment intensity in strategic emerging industry enterprises is higher than that of traditional industries, but sectors like biotechnology, new materials, and energy conservation have lower R&D investment intensity compared to the average level of SOE A-shares (5.86%), indicating a gap with industry leaders [12] Group 4: Sector-Specific Insights - In the new energy sector, SOEs have established a full industrial chain layout covering power generation operations, equipment manufacturing, and technical services, transitioning from "scale competition" to "quality and efficiency competition" [14] - In the new materials sector, advanced steel materials face industry pressures, while advanced non-ferrous metal materials show high profitability and R&D investment, with companies adopting niche market and industry chain extension strategies [16] - In the biotechnology sector, many enterprises are positioned in relatively mature areas like raw materials and trade, but there is insufficient investment in innovative drugs and precision instruments, indicating a need to strengthen overall industry resilience [18] Group 5: Strategic Recommendations - Establish a full-cycle evaluation and adjustment mechanism for emerging industries, transitioning from experience-based to data-driven decision-making [21] - Implement a "one enterprise, one strategy; one industry, one model" incubation path to guide enterprises in selecting flexible combinations of business extensions, platform incubation, equity cooperation, and fund investment [21] - Optimize resource allocation mechanisms driven by innovation and capital, enhancing collaborative innovation resources and establishing special funds for emerging development [21] - Focus on creating an economic empowerment organization characterized by "small teams, large platforms" to enhance industry leadership and ecological construction capabilities [21]

Core Viewpoint - The Ministry of Natural Resources has released the first batch of the "Planning and Land Policy Innovation Case Collection" to promote innovative practices in urban land use and planning across various cities in China [1] Group 1: Key Highlights - The case collection includes 19 exemplary cases from cities such as Beijing, Shanghai, Hangzhou, Guangzhou, Shenzhen, Nanjing, Chengdu, Xi'an, Dalian, Xiangtan, and Zhuzhou [1] - These cases are derived from grassroots practices nationwide, showcasing recent explorations in optimizing planning adjustments, land use conversion rules, and supporting land compatibility and composite utilization [1] - The initiative encourages local governments to proactively devise innovative measures, exploring flexible and efficient resource allocation methods to create a virtuous cycle of "one place innovation, multiple places benefit" [1] Group 2: Policy Implications - The shift in spatial utilization models is emphasized, moving from "incremental expansion" to "stock potential excavation" and from "rigid control" to "flexible adaptation" [1] - The transformation of planning and land policies is aimed at changing the mindset from regulatory thinking to operational thinking, further enhancing and expanding the comprehensive effectiveness of policies [1]

Core Viewpoint - The company, New Industry Biomedical Engineering Co., Ltd., has experienced a decline in stock price and a mixed financial performance, with a slight increase in revenue but a significant decrease in net profit [1][2]. Group 1: Stock Performance - On January 20, the stock price of New Industry fell by 2.05% to 56.76 CNY per share, with a trading volume of 112 million CNY and a turnover rate of 0.29%, resulting in a total market capitalization of 44.597 billion CNY [1]. - Year-to-date, the stock price has increased by 0.91%, but it has decreased by 4.96% over the last five trading days, 3.80% over the last 20 days, and 8.32% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 3.428 billion CNY, representing a year-on-year growth of 0.39%, while the net profit attributable to shareholders was 1.205 billion CNY, reflecting a year-on-year decrease of 12.92% [2]. - Cumulatively, since its A-share listing, the company has distributed a total of 3.86 billion CNY in dividends, with 2.357 billion CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 15.87% to 13,100, with an average of 51,997 circulating shares per shareholder, which is an increase of 18.87% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 26.4824 million shares, an increase of 4.2383 million shares from the previous period [3].

Summary of China Healthcare Conference Call Industry Overview - **Industry**: China Healthcare - **Survey**: AlphaWise survey conducted with 80 hospital executives in November 2025, focusing on hospital capital expenditures (capex), procedure volumes, and brand preferences for 2026 [1][26] Key Findings Hospital Capex Outlook - **Cautiously Optimistic**: 59% of hospital executives expect higher capex in 2026, up from 43% in 2025, but still below 85% in 2024 [3][51] - **Expected Growth**: Average capex growth projected at 4.7% YoY for 2026, compared to 3.0% for 2025 [3][51] - **Actual Growth in 2025**: Estimated capex growth for 2025 was 5.8% YoY, indicating better-than-expected performance [3][51] - **Key Drivers**: Hospital surplus (69%), patient demand (50%), and local fiscal budgets (44%) are primary factors influencing capex decisions [31] Equipment Spending Trends - **Top Equipment Categories**: Surgical and soft endoscopes expected to see the highest unit growth at 26% and 16% respectively, followed by CT, ultrasound, and CLIA analyzers with high-teens growth [32][93] - **AI and Digitization**: AI, digitization, and cloud capabilities are the top investment priorities, with 84% of executives planning to increase spending in these areas [33][78] Brand Preferences and Market Dynamics - **Domestic Brands**: Mindray and United Imaging maintain strong positions in brand preference, with Mindray expected to gain share in surgical endoscopes and ultrasound [36][38] - **Foreign Brands**: Siemens Healthineers, GE Healthcare, and Philips show mixed performance, with potential share losses due to domestic competition [17][19][20] - **Market Shifts**: United Imaging is expected to gain significant share in CT and MR equipment, while Mindray is anticipated to strengthen its position in various categories [38] Pricing and Procurement - **Pricing Pressures**: Continuous pricing pressure expected in clinical testing, negatively impacting the IVD segment [10][42] - **Procurement Changes**: Increased expectations for centralized procurement and shorter tender cycles, which could lead to downward pricing pressures [30][61][62] Procedure Volume Expectations - **Moderating Growth**: Only 17% of executives expect growth in procedure volumes, down from 31% in the previous year, primarily due to budget constraints [39] - **Specialty Procedures**: Expected growth across major specialties is clustered in the mid-single-digit range, indicating stable demand [40] Stock Implications - **Positive Outlook for Certain Companies**: - **Mindray**: Expected to recover to positive revenue growth in 2026 due to stable capex environment [11] - **United Imaging**: Positioned to benefit from high-end imaging demand [12] - **APT Medical**: Anticipated to capture growth in cardiac ablation procedures [14][15] - **Zylox-Tonbridge**: Expected to see growth in neuro and peripheral intervention procedures [16] Risks and Challenges - **Market Uncertainty**: Hospital executives express caution regarding capex decisions, with procurement timing expected to be back-loaded into the second half of 2026 [68] - **Regulatory Pressures**: Ongoing regulatory scrutiny and tighter budgets continue to pose challenges for lower-tier hospitals [56] Conclusion The 2026 outlook for the China healthcare sector is cautiously optimistic, with expected growth in hospital capex and a focus on advanced medical technologies. However, challenges such as pricing pressures and market competition from domestic players remain significant factors influencing the landscape.

Core Insights - Wenzhou, known as the "capital of China's private economy," is transitioning towards a trillion-level economic scale, focusing on new growth points and industrial transformation [1] Group 1: Offshore Wind Power Development - Wenzhou is accelerating the development of deep-sea offshore wind power, with 17 projects planned and a capacity exceeding 20 million kilowatts, accounting for over 50% of the province's total [7] - The deep-sea wind power base in Wenzhou is set to deliver over 50 large offshore wind turbines and complete over 100 overseas orders by 2025 [1][3] Group 2: Manufacturing Investment Growth - Manufacturing investment in Wenzhou increased by 23.9% year-on-year from January to November 2025, driven by significant project implementations [5] Group 3: Artificial Intelligence and Data Integration - Wenzhou is leveraging data elements to support the development of its artificial intelligence industry, with plans to create a 100 billion-level AI industry cluster by 2027 [10] - The city has developed 50 high-quality datasets across various fields, including healthcare and industrial manufacturing, to support the training of vertical AI models [10] Group 4: Traditional Industry Transformation - The automotive and motorcycle parts industry in Wenzhou saw an increase of nearly 20% in value added from January to November 2025, showcasing its ability to maintain growth during transformation [12][21] - Traditional automotive parts are evolving towards high-end and intelligent upgrades, with a complete industrial chain being revitalized in Wenzhou [19] Group 5: Technological Advancements - Investment in technology research and development is creating new growth drivers for traditional industries, with automotive parts companies supplying over 100 vehicle models and producing more than 5,000 product varieties [21]

Core Viewpoint - The State-owned Assets Supervision and Administration Commission (SASAC) emphasizes the need to significantly increase the proportion of value added from strategic emerging industries during the 14th Five-Year Plan period, focusing on optimizing the layout and structural adjustments of state-owned enterprises (SOEs) [1][2]. Group 1: Key Goals for State-owned Enterprises - The total assets of state-owned enterprises under SASAC grew from 235 trillion yuan to 387 trillion yuan during the 14th Five-Year Plan, with an average annual growth rate of 10.5% [2]. - By the end of 2025, local state-owned enterprises achieved a value added of 6.9 trillion yuan and completed fixed asset investments of 5.3 trillion yuan [2]. - The main goals for the 15th Five-Year Plan include enhancing strategic missions, improving contributions to economic and social development, and increasing the number of leading technology enterprises [2][3]. Group 2: Enhancing Capabilities of State-owned Enterprises - SASAC aims to improve five key capabilities of SOEs: value creation, technological innovation, industrial upgrading, reform breakthroughs, and party leadership [3][4]. - In terms of value creation, SOEs are encouraged to focus on long-term value and improve productivity metrics such as labor productivity and asset turnover [3]. - For technological innovation, there is a push for increased investment in basic research and the cultivation of talent to enhance the national innovation system [3][4]. Group 3: Industrial Upgrading and Reform - The focus on industrial upgrading includes promoting intelligent, green, and integrated development, while also strengthening traditional industries and creating new pillar industries [4][5]. - SASAC emphasizes the need for deeper reforms in SOEs to establish a modern corporate governance structure and a market-oriented operational mechanism [4][5]. - The importance of artificial intelligence is highlighted, with support for enterprises to engage in AI-related initiatives and the development of high-value application scenarios [5][6]. Group 4: Investment and Innovation Strategies - SASAC encourages the use of special bonds and loans to support key projects that strengthen supply chains and stimulate demand [5][6]. - There is a call for the establishment of high-level innovation platforms and mechanisms to facilitate the commercialization of research outcomes [6]. - The integration of local industrial policies and resources is crucial for driving the development of emerging pillar industries through internal growth and mergers [6].

Core Viewpoint - The State-owned Assets Supervision and Administration Commission (SASAC) aims to significantly enhance the contribution of state-owned enterprises (SOEs) to the economy during the 14th Five-Year Plan period, with a focus on strategic emerging industries and technological innovation [1][2]. Group 1: Economic Growth and Performance - During the 14th Five-Year Plan period, the total assets of state-owned enterprises under SASAC increased from 235 trillion yuan to 387 trillion yuan, representing an average annual growth of 10.5% [1][2]. - From January to November 2025, local state-owned enterprises achieved a value-added output of 6.9 trillion yuan and completed fixed asset investments of 5.3 trillion yuan [2]. Group 2: Strategic Goals for the 15th Five-Year Plan - The SASAC plans to enhance the strategic mission of SOEs, focusing on strategic security, industry leadership, and public service, while increasing the contribution of state-owned economy to social development [2]. - Key goals include improving self-reliance in technology, increasing the number of leading technology enterprises, optimizing the layout of state-owned capital, and enhancing the vitality of enterprises [2][3]. Group 3: Enhancing Capabilities - SASAC emphasizes the need to improve five key capabilities of SOEs: value creation, technological innovation, industrial upgrading, reform breakthroughs, and party leadership [3][4]. - In terms of value creation, SOEs are encouraged to focus on long-term value and improve productivity metrics such as labor productivity and asset turnover [3]. - For technological innovation, there is a push for increased investment in basic research and the cultivation of talent to enhance the innovation capacity of enterprises [3]. Group 4: Industry Upgrading and Reform - The SASAC aims to guide SOEs in pursuing intelligent, green, and integrated development, while fostering new production capabilities and enhancing the competitiveness of traditional industries [4]. - There is a call for deeper reforms in the governance and operational mechanisms of SOEs to support high-quality development [4]. Group 5: Focus on Technological Innovation and AI - SASAC highlights the importance of artificial intelligence and encourages enterprises to participate in national AI initiatives, aiming to create high-value applications across various industries [6]. - The focus is on fostering collaboration within the industrial chain and promoting the development of emerging pillar industries that can lead future growth [6].